Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal

KEY TAKEAWAYSShares of Catalent soar on news Novo Holdings, the majority owner of Novo Nordisk, is acquiring the syringe maker for $16.5 billion in cash.The deal represents a 16.5% premium over Catalent's pre-announcement stock price Friday.The acquisition expands Novo Nordisk's production capacity and supply flexibility, particularly for its Wegovy weight loss drug.Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo No ...